TrialLupus science & medicine2025

Enpatoran, a first-in-class, selective, orally administered toll-like receptor 7/8 inhibitor, in systemic and cutaneous lupus erythematosus: results from a randomised, placebo-controlled phase Ib study.

Torsten Witte et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.